Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis

Journal of Neuroimmunology

Volumn 268, Issue 1-2, 2014, Pages 95-98

  Sato, Douglas Kazutoshi ^a   Nakashima, Ichiro ^a   Bar Or, Amit ^b   Misu, Tatsuro ^c   Suzuki, Chihiro ^a   Nishiyama, Shuhei ^a   Kuroda, Hiroshi ^a   Fujihara, Kazuo ^c   Aoki, Masashi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MCGILL UNIVERSITY   (Canada)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Fingolimod; Interleukin 17; Multiple sclerosis; Regulatory T cells; Th17; Treatment

Indexed keywords

FINGOLIMOD;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOOT DISEASE; HUMAN; HYPESTHESIA; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; SENSORY DYSFUNCTION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TREATMENT OUTCOME; UPREGULATION;

FINGOLIMOD; INTERLEUKIN-17; MULTIPLE SCLEROSIS; REGULATORY T CELLS; TH17; TREATMENT;

CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84896737267     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.01.008     Document Type: Article

References (16)

1. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., Parente E., Fili L., Ferri S., Frosali F., Giudici F., Romagnani P., Parronchi P., Tonelli F., Maggi E., Romagnani S. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204:1849-1861.
2. Castrop F., Kowarik M.C., Albrecht H., Krause M., Haslinger B., Zimmer C., Berthele A., Hemmer B. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?. Neurology 2012, 78:928-930.
3. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., Pelletier J., Capra R., Gallo P., Izquierdo G., Tiel-Wilck K., de Vera A., Jin J., Stites T., Wu S., Aradhye S., Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:402-415.
4. Daelman L., Maitrot A., Maarouf A., Chaunu M.P., Papeix C., Tourbah A. Severe multiple sclerosis reactivation under fingolimod 3months after natalizumab withdrawal. Mult. Scler. 2012, 18:1647-1649.
5. Darlington P.J., Touil T., Doucet J.-S., Gaucher D., Zeidan J., Gauchat D., Corsini R., Kim H.J., Duddy M., Jalili F., Arbour N., Kebir H., Chen J., Arnold D.L., Bowman M., Antel J., Prat A., Freedman M.S., Atkins H., Sekaly R., Cheynier R., Bar-Or A., for the Canadian, M.S.B.M.T.S.G Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann. Neurol. 2013, 73:341-354.
6. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., Weaver C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6:1123-1132.
7. Kappos L., Radue E.W., O'Connor P., Polman C., Hohlfeld R., Calabresi P., Selmaj K., Agoropoulou C., Leyk M., Zhang-Auberson L., Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:387-401.
8. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
9. Kovarik J.M., Schmouder R., Barilla D., Riviere G.J., Wang Y., Hunt T. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J. Clin. Pharmacol. 2004, 44:532-537.
10. Mehling M., Brinkmann V., Antel J., Bar-Or A., Goebels N., Vedrine C., Kristofic C., Kuhle J., Lindberg R.L., Kappos L. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008, 71:1261-1267.
11. Mehling M., Lindberg R., Raulf F., Kuhle J., Hess C., Kappos L., Brinkmann V. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010, 75:403-410.
12. Mehling M., Johnson T.A., Antel J., Kappos L., Bar-Or A. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011, 76:S20-S27.
13. Montes M., Zhang X., Berthelot L., Laplaud D.-A., Brouard S., Jin J., Rogan S., Armao D., Jewells V., Soulillou J.-P., Markovic-Plese S. Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. Clin. Immunol. 2009, 130:133-144.
14. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
15. Saida T., Kikuchi S., Itoyama Y., Hao Q., Kurosawa T., Nagato K., Tang D., Zhang-Auberson L., Kira J. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult. Scler. 2012, 18:1269-1277.
16. Yokoseki A., Saji E., Arakawa M., Hokari M., Ishiguro T., Yanagimura F., Ishihara T., Okamoto K., Nishizawa M., Kawachi I. Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy. Mult. Scler. 2013, 19:1230-1233.